Francesca Amadori, Elena Bardellini, Federica Veneri, Alessandra Majorana
{"title":"光生物调节激光治疗寻常型天疱疮口腔病变:一项随机、双盲、对照研究。","authors":"Francesca Amadori, Elena Bardellini, Federica Veneri, Alessandra Majorana","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Systemic corticosteroids are the mainstay treatment for PV oral lesions; the aim of this study is to evaluate the efficacy of PBMT with a 645 nm diode laser as a supportive topical therapy in patients with PV induced erosive-ulcerative oral lesions.</p><p><strong>Materials and methods: </strong>This double-blind placebo-controlled study divided patients into two groups: A, patients receiving laser therapy (Raffaello 980 Bio, Dental Medical Technologies, Italy with the following parameters: 100 mW power, 645 nm wave length, irradiation area 1 cm<sup>2</sup>, application time 30 sec/cm<sup>2</sup>, energy density 3 J/cm<sup>2</sup>, scanning modality) and B, receiving sham therapy (placebo). All patients were being treated also with a systemic corticosteroid therapy i.e. prednisone 0.5 mg/Kg per day. Size of lesions, VAS and satisfaction were evaluated before the treatment (T0), after 4 weeks (T1) and after 8 weeks as a follow-up (T2).</p><p><strong>Results: </strong>A total of 50 lesions were evaluated. About lesions size, there was a statistical significative difference between the two groups just at T2 (p=0.0193), though VAS significantly decreased both at T1 (p=0.0198) and at T2 (p=0.0087). In general, all patients were satisfied of the treatment received.</p><p><strong>Conclusion: </strong>PBMT can be considered a validate supportive therapeutic option, even if further RCTs studies with wide sample sizes and standardized management protocols are suggested.</p>","PeriodicalId":35508,"journal":{"name":"Stomatologija","volume":"24 3","pages":"80-84"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Photobiomodulation laser therapy in pemphigus vulgaris oral lesions: A randomized, double-blind, controlled study.\",\"authors\":\"Francesca Amadori, Elena Bardellini, Federica Veneri, Alessandra Majorana\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Systemic corticosteroids are the mainstay treatment for PV oral lesions; the aim of this study is to evaluate the efficacy of PBMT with a 645 nm diode laser as a supportive topical therapy in patients with PV induced erosive-ulcerative oral lesions.</p><p><strong>Materials and methods: </strong>This double-blind placebo-controlled study divided patients into two groups: A, patients receiving laser therapy (Raffaello 980 Bio, Dental Medical Technologies, Italy with the following parameters: 100 mW power, 645 nm wave length, irradiation area 1 cm<sup>2</sup>, application time 30 sec/cm<sup>2</sup>, energy density 3 J/cm<sup>2</sup>, scanning modality) and B, receiving sham therapy (placebo). All patients were being treated also with a systemic corticosteroid therapy i.e. prednisone 0.5 mg/Kg per day. Size of lesions, VAS and satisfaction were evaluated before the treatment (T0), after 4 weeks (T1) and after 8 weeks as a follow-up (T2).</p><p><strong>Results: </strong>A total of 50 lesions were evaluated. About lesions size, there was a statistical significative difference between the two groups just at T2 (p=0.0193), though VAS significantly decreased both at T1 (p=0.0198) and at T2 (p=0.0087). In general, all patients were satisfied of the treatment received.</p><p><strong>Conclusion: </strong>PBMT can be considered a validate supportive therapeutic option, even if further RCTs studies with wide sample sizes and standardized management protocols are suggested.</p>\",\"PeriodicalId\":35508,\"journal\":{\"name\":\"Stomatologija\",\"volume\":\"24 3\",\"pages\":\"80-84\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stomatologija\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Dentistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stomatologija","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Dentistry","Score":null,"Total":0}
Photobiomodulation laser therapy in pemphigus vulgaris oral lesions: A randomized, double-blind, controlled study.
Objective: Systemic corticosteroids are the mainstay treatment for PV oral lesions; the aim of this study is to evaluate the efficacy of PBMT with a 645 nm diode laser as a supportive topical therapy in patients with PV induced erosive-ulcerative oral lesions.
Materials and methods: This double-blind placebo-controlled study divided patients into two groups: A, patients receiving laser therapy (Raffaello 980 Bio, Dental Medical Technologies, Italy with the following parameters: 100 mW power, 645 nm wave length, irradiation area 1 cm2, application time 30 sec/cm2, energy density 3 J/cm2, scanning modality) and B, receiving sham therapy (placebo). All patients were being treated also with a systemic corticosteroid therapy i.e. prednisone 0.5 mg/Kg per day. Size of lesions, VAS and satisfaction were evaluated before the treatment (T0), after 4 weeks (T1) and after 8 weeks as a follow-up (T2).
Results: A total of 50 lesions were evaluated. About lesions size, there was a statistical significative difference between the two groups just at T2 (p=0.0193), though VAS significantly decreased both at T1 (p=0.0198) and at T2 (p=0.0087). In general, all patients were satisfied of the treatment received.
Conclusion: PBMT can be considered a validate supportive therapeutic option, even if further RCTs studies with wide sample sizes and standardized management protocols are suggested.